April 11, 2014 08:41 AM Eastern Daylight Time
CAMBRIDGE, Mass.-(BUSINESS WIRE)-GnuBIO, a privately-held life sciences company that has developed a droplet-based DNA sequencing technology, today announced that it was acquired by Bio-Rad Laboratories, Inc. With this acquisition, Bio-Rad will expand its Digital Biology Center and establish a research and development site in Cambridge, Massachusetts.
GnuBIO, has developed a DNA sequencing solution that integrates the entire sample preparation workflow on a chip, from sample capture, PCR, and sequencing, to informatics. This capability offers a “Sample In, Answer Out” DNA sequencing solution whereby a technician or researcher simply loads genomic DNA into the cartridge and presses a button to start the run with results delivered within hours, versus days.
“Bio-Rad’s leading positions in the clinical IVD market as well as the Droplet Digital™ PCR space make Bio-Rad the ideal acquisition partner for us,” said John Boyce, President, CEO, and Founder of GnuBIO. “Bio-Rad’s reputation as well as its presence in both the clinical and research markets will be essential elements to the success of the GnuBIO platform. We are very excited to join the Bio-Rad family,” Boyce added.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) designs, manufactures, and distributes a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 7,750 people worldwide and had revenues exceeding $2.1 billion in 2013. For more information, visit our website at www.bio-rad.com.
About GnuBIO
Based in Cambridge, Massachusetts, GnuBIO is developing a droplet-based DNA sequencing platform. The innovative system is the first fully-integrated DNA sequencing platform that utilizes microfluidic and emulsion technology to perform complex, multiplexed reactions in droplets. This will allow both researchers and clinicians in the future to perform complete DNA sequencing workflows in a few hours instead of days.
Contacts
GnuBIO, Inc
Susie Harborth, 617-446-6742
Chief Financial Officer
[email protected]
www.gnubio.com